Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study-Reference-Cited by-同舟云学术

Gaboxadol in angelman syndrome: A double-blind, parallel-group, randomized placebo-controlled phase 3 study

Published:2023-11 Issue: Volume:47 Page:6-12
ISSN:1090-3798
Container-title:European Journal of Paediatric Neurology
language:en
Short-container-title:European Journal of Paediatric Neurology

Author:

Keary Christopher^ORCID,Bird Lynne M.^ORCID,de Wit Marie-Claire,Hatti Shivkumar,Heimer Gali,Heussler Helen,Kolevzon Alexander,Mathews Adera,Ochoa-Lubinoff Cesar,Tan Wen-Hann,Yan Ying^ORCID,Adams Maxwell^ORCID

Publisher

Elsevier BV

Subject

Neurology (clinical),General Medicine,Pediatrics, Perinatology and Child Health

Reference28 articles.

1. Is Angelman syndrome an alternate result of del(15)(q11q13)?;Magenis;Am. J. Med. Genet.,1987

2. Angelman syndrome, a genomic imprinting disorder of the brain;Chamberlain;J. Neurosci.,2010

3. Dagli AI, Mueller J, Williams CA: Angelman Syndrome. GeneReviews®. Posted September 15, 1998. Revised December 21, 2017. Available at: ncbi.nlm.nih.gov/books/NBK1144/[Accessed March 28, 2022].

4. Loss of nuclear UBE3A activity is the predominant cause of Angelman syndrome in individuals carrying UBE3A missense mutations;Bossuyt;Hum. Mol. Genet.,2021

5. Pharmacological therapies for Angelman syndrome;Tan;Wien Med. Wochenschr.,2017

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Classics in Chemical Neuroscience: Muscimol;ACS Chemical Neuroscience;2024-09-10

2. What Is the Role of the "GABA Tone" in Normal and Pathological Conditions?;Neurology;2024-02-27

3. Enhancing GABAergic Tonic Inhibition Reduces Seizure-Like Activity in the Neonatal Mouse Hippocampus and Neocortex;The Journal of Neuroscience;2024-01-04

4. Translational research for the development of treatment of patients with neurogenetic diseases: An important step for Angelman syndrome;European Journal of Paediatric Neurology;2023-11

5. Looking at eye tracking’s potential for clinical trials;Spectrum;2023